AKT1 and melanoma: Using orthotopic preclinical models of anti-PD1 resistant, immune ‘cold’ melanoma (B16F10), the pharmacologic inhibition of AKT and WEE1 via AZD5363 (capivasertib) and MK1775 (adavosertib), respectively, was able to induce robust anti-PD1 responsiveness.